“A place for everything, everything in its place”
Ben Franklin
The Three Pillars of Systemic Therapy First: Why This Sequencing Works
At Mederi Care, our systemic-therapy-first approach rests on three fundamental advantages that transform cancer treatment from a local intervention into a comprehensive healing protocol.
1. Comprehensive Protocol That Addresses All Three Elements
When we begin with systemic therapy, we’re not simply attacking the tumor—we’re addressing the entire cancer ecosystem. Our protocol comprehensively targets three critical elements: the HOST (the patient’s body, constitution, vitality, immune system, and internal terrain, stressors etc.), the MICRO-ENVIRONMENT (the interplay between the Host and Tumor (lab test) such as the tissue and vascular environment surrounding where the cancer grows), and the TUMOR itself (Pathology of tumor, molecular proofing from pathology or liquid biopsy or from blood), including cancer stem cells.
This matters profoundly. Modern cancer biology has taught us that cancer isn’t just a collection of malignant cells—it’s a complex system involving immune dysfunction, metabolic dysregulation, chronic inflammation, and a permissive microenvironment that allows cancer to thrive. When we address the cancer and the person systemically first, we’re not just killing visible cancer cells—we’re transforming the conditions that allow cancer to exist in the first place. We’re strengthening immune surveillance, reducing systemic inflammation, disrupting the metabolic pathways that feed cancer growth, and targeting cancer stem cells that drive recurrence.
This comprehensive approach provides the best long-term outcomes because it addresses the root causes of cancer persistence and recurrence, not just the visible tumor mass.
2. Proof of Efficacy: Measurable Feedback Before Intervention
One of the most valuable aspects of starting with systemic therapy is that it provides us with crucial evidence: if the systemic therapy is effective, the tumor should shrink. This shrinkage isn’t just encouraging—it’s essential feedback that the protocol is positively affecting the cancer at a cellular and systemic level.
We see this consistently in our practice. When patients undergo comprehensive systemic therapy for several weeks to months before any local intervention, imaging studies typically show measurable tumor reduction. This provides both the patient and the physician with real, objective confirmation that the botanicals, immunonutrients, and systemic treatments are working. We’re not operating on faith—we’re operating on evidence.
This feedback loop is invaluable. It tells us that the internal terrain is shifting in the right direction, that the immune system is engaging more effectively, and that the cancer is responding to our comprehensive approach. It gives patients confidence in their protocol and allows us to refine and optimize treatment before any invasive procedure.
3. Tumor Downstaging: Treating a Smaller, Less Aggressive Target
Perhaps the most practical advantage of systemic therapy first is tumor downstaging. By starting with comprehensive systemic treatment, we can often downgrade the tumor—making it significantly smaller—so that when the surgical or cryoablation intervention occurs, we’re treating a much smaller, less aggressive target.
This has cascading benefits. A smaller tumor means less tissue needs to be treated or removed. Less tissue trauma means reduced perioperative inflammatory response, less immune suppression, and faster healing. In breast cancer, a tumor that shrinks from 1.5 cm to 0.8 cm requires a smaller ablation zone, preserving more healthy breast tissue and improving cosmetic outcomes. In prostate cancer, tumor reduction can mean the difference between needing whole-gland treatment versus focal therapy that preserves sexual and urinary function.
We’re essentially using systemic therapy to create the optimal conditions for minimally invasive intervention—smaller target, healthier surrounding tissue, optimized immune function, and a body prepared to heal rather than inflame.
This is why sequencing matters. It’s not just about doing the right things—it’s about doing them in the right order, at the right time, to create the best possible outcomes for long-term cancer control and quality of life.
This is where cryoablation offers a distinct advantage within our sequenced approach. Because cryoablation involves minimal tissue trauma—a needle rather than an incision, targeted freezing rather than extensive tissue removal—it generates a significantly reduced perioperative inflammatory response compared to traditional surgery. The immune suppression is minimal. The stress to the body is dramatically lower. When properly sequenced after systemic preparation and followed by continued immune support, cryoablation allows us to eliminate local disease while preserving the body’s capacity to resist metastatic progression.
We’re not suggesting that surgery isn’t important—it absolutely is. We’re saying that careful planning of when surgery should happen, combined with proper preparation and continued support, transforms surgery from a potential trigger for metastatic acceleration into a precisely-timed intervention within a comprehensive healing protocol.
Conclusion
Cancer treatment is about more than removing or destroying a tumor. It is also about understanding the patient, the environment surrounding the tumor, and the biological factors that may allow cancer to grow or return. At the Mederi Care Clinic our systemic-therapy-first approach is designed to address these interconnected factors while preparing the patient for a carefully planned local treatment.
By monitoring the tumor’s response before intervention, we can gather valuable information, adjust the treatment plan, and help guide decisions about the timing and extent of surgery or ablation. When appropriate, reducing the size of a tumor before local treatment may create opportunities to preserve more healthy tissue and support recovery. Cryoablation also offers a less invasive option for qualified patients.
The goal is not to delay necessary treatment, but to make informed decisions about the safest and most effective sequence of care. Systemic therapy, surgery, and cryoablation each have a role, depending on the cancer type, stage, and individual patient. Any decision to change the timing of surgery should be made with the patient’s oncology and surgical team, based on established evidence and the risks of waiting.
Ultimately, timing matters—but so does choosing the right treatment for the right patient. A thoughtful, coordinated approach can help patients pursue effective cancer control while protecting their health, function, and quality of life.
